 | • レポートコード：D0GIR-11236 • 出版社/出版日：GlobalInfoResearch / 2020年9月23日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、108ページ • 納品方法：Eメール • 産業分類：医療、製薬、バイオ |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、アダリムマブの世界市場を広く調査・分析し、今後の市場展望をまとめております。アダリムマブの種類別市場規模（経口タイプ、注射タイプ）、用途別市場規模（関節リウマチ、乾癬、クローン病、潰瘍性大腸炎、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・メーカー情報（販売量、市場シェア、製品概要、SWOT分析）：AbbVie, Inc.、Eisai Co., Ltd.、Amgen, Inc.、Pfizer, Inc.、Boehringer Ingelheim GmbH、Novartis AG、Mylan N.V. ・地域別グローバル市場分析 2015年-2020年 ・アダリムマブの北米市場（アメリカ、カナダ、メキシコ） ・アダリムマブのヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・アダリムマブのアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・アダリムマブの南米市場（ブラジル、アルゼンチン） ・アダリムマブの中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：経口タイプ、注射タイプ ・用途別分析：関節リウマチ、乾癬、クローン病、潰瘍性大腸炎、その他 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The global Adalimumab market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 0.2% in the forecast period of 2020 to 2025 and will expected to reach USD 882.4 million by 2025, from USD 874.8 million in 2019.
The Adalimumab market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Adalimumab market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Adalimumab market has been segmented into
Oral Type
Injection Type
By Application, Adalimumab has been segmented into:
Rheumatoid Arthritis
Psoriasis
Crohn’s Disease
Ulcerative Colitis
Others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Adalimumab market presented in the report. This section sheds light on the sales growth of different regional and country-level Adalimumab markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Adalimumab market.
The report offers in-depth assessment of the growth and other aspects of the Adalimumab market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Adalimumab Market Share Analysis
Adalimumab competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Adalimumab sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Adalimumab sales, revenue and market share for each player covered in this report.
The major players covered in Adalimumab are:
AbbVie, Inc.
Eisai Co., Ltd.
Amgen, Inc.
Pfizer, Inc.
Boehringer Ingelheim GmbH
Novartis AG
Mylan N.V.
Among other players domestic and global, Adalimumab market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Adalimumab product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Adalimumab, with price, sales, revenue and global market share of Adalimumab in 2018 and 2019.
Chapter 3, the Adalimumab competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Adalimumab breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Adalimumab market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Adalimumab sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 Adalimumab Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Adalimumab Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Oral Type
1.2.3 Injection Type
1.3 Market Analysis by Application
1.3.1 Overview: Global Adalimumab Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Rheumatoid Arthritis
1.3.3 Psoriasis
1.3.4 Crohn’s Disease
1.3.5 Ulcerative Colitis
1.3.6 Others
1.4 Overview of Global Adalimumab Market
1.4.1 Global Adalimumab Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 AbbVie, Inc.
2.1.1 AbbVie, Inc. Details
2.1.2 AbbVie, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 AbbVie, Inc. SWOT Analysis
2.1.4 AbbVie, Inc. Product and Services
2.1.5 AbbVie, Inc. Adalimumab Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Eisai Co., Ltd.
2.2.1 Eisai Co., Ltd. Details
2.2.2 Eisai Co., Ltd. Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Eisai Co., Ltd. SWOT Analysis
2.2.4 Eisai Co., Ltd. Product and Services
2.2.5 Eisai Co., Ltd. Adalimumab Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Amgen, Inc.
2.3.1 Amgen, Inc. Details
2.3.2 Amgen, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Amgen, Inc. SWOT Analysis
2.3.4 Amgen, Inc. Product and Services
2.3.5 Amgen, Inc. Adalimumab Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Pfizer, Inc.
2.4.1 Pfizer, Inc. Details
2.4.2 Pfizer, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Pfizer, Inc. SWOT Analysis
2.4.4 Pfizer, Inc. Product and Services
2.4.5 Pfizer, Inc. Adalimumab Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Boehringer Ingelheim GmbH
2.5.1 Boehringer Ingelheim GmbH Details
2.5.2 Boehringer Ingelheim GmbH Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Boehringer Ingelheim GmbH SWOT Analysis
2.5.4 Boehringer Ingelheim GmbH Product and Services
2.5.5 Boehringer Ingelheim GmbH Adalimumab Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Novartis AG
2.6.1 Novartis AG Details
2.6.2 Novartis AG Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Novartis AG SWOT Analysis
2.6.4 Novartis AG Product and Services
2.6.5 Novartis AG Adalimumab Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 Mylan N.V.
2.7.1 Mylan N.V. Details
2.7.2 Mylan N.V. Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Mylan N.V. SWOT Analysis
2.7.4 Mylan N.V. Product and Services
2.7.5 Mylan N.V. Adalimumab Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Adalimumab Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Adalimumab Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Adalimumab Manufacturer Market Share in 2019
3.3.2 Top 6 Adalimumab Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Adalimumab Sales, Revenue and Market Share by Regions
4.1.1 Global Adalimumab Sales and Market Share by Regions (2015-2020)
4.1.2 Global Adalimumab Revenue and Market Share by Regions (2015-2020)
4.2 North America Adalimumab Sales and Growth Rate (2015-2020)
4.3 Europe Adalimumab Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Adalimumab Sales and Growth Rate (2015-2020)
4.5 South America Adalimumab Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Adalimumab Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Adalimumab Sales, Revenue and Market Share by Country
5.1.1 North America Adalimumab Sales and Market Share by Country (2015-2020)
5.1.2 North America Adalimumab Revenue and Market Share by Country (2015-2020)
5.2 United States Adalimumab Sales and Growth Rate (2015-2020)
5.3 Canada Adalimumab Sales and Growth Rate (2015-2020)
5.4 Mexico Adalimumab Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Adalimumab Sales, Revenue and Market Share by Country
6.1.1 Europe Adalimumab Sales and Market Share by Country (2015-2020)
6.1.2 Europe Adalimumab Revenue and Market Share by Country (2015-2020)
6.2 Germany Adalimumab Sales and Growth Rate (2015-2020)
6.3 UK Adalimumab Sales and Growth Rate (2015-2020)
6.4 France Adalimumab Sales and Growth Rate (2015-2020)
6.5 Russia Adalimumab Sales and Growth Rate (2015-2020)
6.6 Italy Adalimumab Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Adalimumab Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Adalimumab Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Adalimumab Revenue and Market Share by Regions (2015-2020)
7.2 China Adalimumab Sales and Growth Rate (2015-2020)
7.3 Japan Adalimumab Sales and Growth Rate (2015-2020)
7.4 Korea Adalimumab Sales and Growth Rate (2015-2020)
7.5 India Adalimumab Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Adalimumab Sales and Growth Rate (2015-2020)
7.7 Australia Adalimumab Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Adalimumab Sales, Revenue and Market Share by Country
8.1.1 South America Adalimumab Sales and Market Share by Country (2015-2020)
8.1.2 South America Adalimumab Revenue and Market Share by Country (2015-2020)
8.2 Brazil Adalimumab Sales and Growth Rate (2015-2020)
8.3 Argentina Adalimumab Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Adalimumab Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Adalimumab Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Adalimumab Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Adalimumab Sales and Growth Rate (2015-2020)
9.3 Turkey Adalimumab Sales and Growth Rate (2015-2020)
9.4 Egypt Adalimumab Sales and Growth Rate (2015-2020)
9.5 South Africa Adalimumab Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Adalimumab Sales and Market Share by Type (2015-2020)
10.2 Global Adalimumab Revenue and Market Share by Type (2015-2020)
10.3 Global Adalimumab Price by Type (2015-2020)
11 Global Adalimumab Market Segment by Application
11.1 Global Adalimumab Sales Market Share by Application (2015-2020)
11.2 Global Adalimumab Revenue Market Share by Application (2015-2020)
11.3 Global Adalimumab Price by Application (2015-2020)
12 Market Forecast
12.1 Global Adalimumab Sales, Revenue and Growth Rate (2021-2025)
12.2 Adalimumab Market Forecast by Regions (2021-2025)
12.2.1 North America Adalimumab Market Forecast (2021-2025)
12.2.2 Europe Adalimumab Market Forecast (2021-2025)
12.2.3 Asia-Pacific Adalimumab Market Forecast (2021-2025)
12.2.4 South America Adalimumab Market Forecast (2021-2025)
12.2.5 Middle East & Africa Adalimumab Market Forecast (2021-2025)
12.3 Adalimumab Market Forecast by Type (2021-2025)
12.3.1 Global Adalimumab Sales Forecast by Type (2021-2025)
12.3.2 Global Adalimumab Market Share Forecast by Type (2021-2025)
12.4 Adalimumab Market Forecast by Application (2021-2025)
12.4.1 Global Adalimumab Sales Forecast by Application (2021-2025)
12.4.2 Global Adalimumab Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Adalimumab Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Adalimumab by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Adalimumab Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. AbbVie, Inc. Basic Information, Manufacturing Base and Competitors
Table 8. AbbVie, Inc. Adalimumab Major Business
Table 9. AbbVie, Inc. Adalimumab Total Revenue (USD Million) (2018-2019)
Table 10. AbbVie, Inc. SWOT Analysis
Table 11. AbbVie, Inc. Adalimumab Product and Services
Table 12. AbbVie, Inc. Adalimumab Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Eisai Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 14. Eisai Co., Ltd. Adalimumab Major Business
Table 15. Eisai Co., Ltd. Adalimumab Total Revenue (USD Million) (2018-2019)
Table 16. Eisai Co., Ltd. SWOT Analysis
Table 17. Eisai Co., Ltd. Adalimumab Product and Services
Table 18. Eisai Co., Ltd. Adalimumab Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. Amgen, Inc. Basic Information, Manufacturing Base and Competitors
Table 20. Amgen, Inc. Adalimumab Major Business
Table 21. Amgen, Inc. Adalimumab Total Revenue (USD Million) (2018-2019)
Table 22. Amgen, Inc. SWOT Analysis
Table 23. Amgen, Inc. Adalimumab Product and Services
Table 24. Amgen, Inc. Adalimumab Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. Pfizer, Inc. Basic Information, Manufacturing Base and Competitors
Table 26. Pfizer, Inc. Adalimumab Major Business
Table 27. Pfizer, Inc. Adalimumab Total Revenue (USD Million) (2018-2019)
Table 28. Pfizer, Inc. SWOT Analysis
Table 29. Pfizer, Inc. Adalimumab Product and Services
Table 30. Pfizer, Inc. Adalimumab Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. Boehringer Ingelheim GmbH Basic Information, Manufacturing Base and Competitors
Table 32. Boehringer Ingelheim GmbH Adalimumab Major Business
Table 33. Boehringer Ingelheim GmbH Adalimumab Total Revenue (USD Million) (2018-2019)
Table 34. Boehringer Ingelheim GmbH SWOT Analysis
Table 35. Boehringer Ingelheim GmbH Adalimumab Product and Services
Table 36. Boehringer Ingelheim GmbH Adalimumab Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 38. Novartis AG Adalimumab Major Business
Table 39. Novartis AG Adalimumab Total Revenue (USD Million) (2018-2019)
Table 40. Novartis AG SWOT Analysis
Table 41. Novartis AG Adalimumab Product and Services
Table 42. Novartis AG Adalimumab Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. Mylan N.V. Basic Information, Manufacturing Base and Competitors
Table 44. Mylan N.V. Adalimumab Major Business
Table 45. Mylan N.V. Adalimumab Total Revenue (USD Million) (2018-2019)
Table 46. Mylan N.V. SWOT Analysis
Table 47. Mylan N.V. Adalimumab Product and Services
Table 48. Mylan N.V. Adalimumab Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 49. Global Adalimumab Sales by Manufacturer (2018-2019) (K Units)
Table 50. Global Adalimumab Revenue by Manufacturer (2018-2019) (USD Million)
Table 51. Global Adalimumab Sales by Regions (2015-2020) (K Units)
Table 52. Global Adalimumab Sales Market Share by Regions (2015-2020)
Table 53. Global Adalimumab Revenue by Regions (2015-2020) (USD Million)
Table 54. North America Adalimumab Sales by Countries (2015-2020) (K Units)
Table 55. North America Adalimumab Sales Market Share by Countries (2015-2020)
Table 56. North America Adalimumab Revenue by Countries (2015-2020) (USD Million)
Table 57. North America Adalimumab Revenue Market Share by Countries (2015-2020)
Table 58. Europe Adalimumab Sales by Countries (2015-2020) (K Units)
Table 59. Europe Adalimumab Sales Market Share by Countries (2015-2020)
Table 60. Europe Adalimumab Revenue by Countries (2015-2020) (USD Million)
Table 61. Asia-Pacific Adalimumab Sales by Regions (2015-2020) (K Units)
Table 62. Asia-Pacific Adalimumab Sales Market Share by Regions (2015-2020)
Table 63. Asia-Pacific Adalimumab Revenue by Regions (2015-2020) (USD Million)
Table 64. South America Adalimumab Sales by Countries (2015-2020) (K Units)
Table 65. South America Adalimumab Sales Market Share by Countries (2015-2020)
Table 66. South America Adalimumab Revenue by Countries (2015-2020) (USD Million)
Table 67. South America Adalimumab Revenue Market Share by Countries (2015-2020)
Table 68. Middle East & Africa Adalimumab Sales by Countries (2015-2020) (K Units)
Table 69. Middle East & Africa Adalimumab Sales Market Share by Countries (2015-2020)
Table 70. Middle East & Africa Adalimumab Revenue by Countries (2015-2020) (USD Million)
Table 71. Middle East & Africa Adalimumab Revenue Market Share by Countries (2015-2020)
Table 72. Global Adalimumab Sales by Type (2015-2020) (K Units)
Table 73. Global Adalimumab Sales Share by Type (2015-2020)
Table 74. Global Adalimumab Revenue by Type (2015-2020) (USD Million)
Table 75. Global Adalimumab Revenue Share by Type (2015-2020)
Table 76. Global Adalimumab Sales by Application (2015-2020) (K Units)
Table 77. Global Adalimumab Sales Share by Application (2015-2020)
Table 78. Global Adalimumab Sales Forecast by Regions (2021-2025) (K Units)
Table 79. Global Adalimumab Market Share Forecast by Regions (2021-2025)
Table 80. Global Adalimumab Sales Forecast by Type (2021-2025) (K Units)
Table 81. Global Adalimumab Market Share Forecast by Type (2021-2025)
Table 82. Global Adalimumab Sales Forecast by Application (2021-2025)
Table 83. Global Adalimumab Market Share Forecast by Application (2021-2025)
Table 84. Direct Channel Pros & Cons
Table 85. Indirect Channel Pros & Cons
Table 86. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Adalimumab Picture
Figure 2. Global Sales Market Share of Adalimumab by Type in 2019
Figure 3. Oral Type Picture
Figure 4. Injection Type Picture
Figure 5. Adalimumab Sales Market Share by Application in 2018
Figure 6. Rheumatoid Arthritis Picture
Figure 7. Psoriasis Picture
Figure 8. Crohn’s Disease Picture
Figure 9. Ulcerative Colitis Picture
Figure 10. Others Picture
Figure 11. Global Adalimumab Market Status and Outlook (2015-2025) (USD Million)
Figure 12. United States Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 13. Canada Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 14. Mexico Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 15. Germany Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 16. France Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 17. UK Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 18. Russia Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 19. Italy Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 20. China Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Japan Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 22. Korea Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 23. India Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Southeast Asia Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 25. Australia Adalimumab Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 26. Brazil Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Egypt Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 28. Saudi Arabia Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 29. South Africa Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 30. Turkey Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 31. Global Adalimumab Sales Market Share by Manufacturer in 2019
Figure 32. Global Adalimumab Revenue Market Share by Manufacturer in 2019
Figure 33. Top 3 Adalimumab Manufacturer (Revenue) Market Share in 2019
Figure 34. Top 6 Adalimumab Manufacturer (Revenue) Market Share in 2019
Figure 35. Key Manufacturer Market Share Trend
Figure 36. Global Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 37. Global Adalimumab Revenue and Growth Rate (2015-2020) (USD Million)
Figure 38. Global Adalimumab Revenue Market Share by Regions (2015-2020)
Figure 39. Global Adalimumab Revenue Market Share by Regions in 2018
Figure 40. North America Adalimumab Sales and Growth Rate (2015-2020)
Figure 41. Europe Adalimumab Sales and Growth Rate (2015-2020)
Figure 42. Asia-Pacific Adalimumab Sales and Growth Rate (2015-2020)
Figure 43. South America Adalimumab Sales and Growth Rate (2015-2020)
Figure 44. Middle East & Africa Adalimumab Sales and Growth Rate (2015-2020)
Figure 45. North America Adalimumab Revenue and Growth Rate (2015-2020) (USD Million)
Figure 46. North America Adalimumab Sales Market Share by Countries (2015-2020)
Figure 47. North America Adalimumab Sales Market Share by Countries in 2018
Figure 48. North America Adalimumab Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 49. North America Adalimumab Revenue Market Share by Countries in 2018
Figure 50. United States Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 51. Canada Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 52. Mexico Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 53. Europe Adalimumab Revenue and Growth Rate (2015-2020) (USD Million)
Figure 54. Europe Adalimumab Revenue Market Share by Countries (2015-2020)
Figure 55. Europe Adalimumab Revenue Market Share by Countries in 2019
Figure 56. Germany Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 57. UK Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 58. France Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 59. Russia Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 60. Italy Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 61. Asia-Pacific Adalimumab Revenue and Growth Rate (2015-2020) (USD Million)
Figure 62. Asia-Pacific Adalimumab Sales Market Share by Regions 2019
Figure 63. Asia-Pacific Adalimumab Revenue Market Share by Regions 2019
Figure 64. China Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 65. Japan Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 66. Korea Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 67. India Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 68. Southeast Asia Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 69. South America Adalimumab Revenue and Growth Rate (2015-2020) (USD Million)
Figure 70. South America Adalimumab Sales Market Share by Countries in 2019
Figure 71. South America Adalimumab Revenue Market Share by Countries in 2019
Figure 72. Brazil Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 73. Argentina Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 74. Middle East and Africa Adalimumab Revenue and Growth Rate (2015-2020) (USD Million)
Figure 75. Middle East and Africa Adalimumab Sales Market Share by Countries in 2019
Figure 76. Middle East and Africa Adalimumab Revenue Market Share by Countries (2015-2020)
Figure 77. Middle East and Africa Adalimumab Revenue Market Share by Countries in 2019
Figure 78. Saudi Arabia Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 79. Egypt Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 80. Turkey Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 81. South Africa Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 82. Global Adalimumab Sales and Growth Rate (2021-2025) (K Units)
Figure 83. Global Adalimumab Revenue and Growth Rate (2021-2025) (USD Million)
Figure 84. North America Sales Adalimumab Market Forecast (2021-2025) (K Units)
Figure 85. Europe Sales Adalimumab Market Forecast (2021-2025) (K Units)
Figure 86. Asia-Pacific Sales Adalimumab Market Forecast (2021-2025) (K Units)
Figure 87. South America Sales Adalimumab Market Forecast (2021-2025) (K Units)
Figure 88. Middle East & Africa Sales Adalimumab Market Forecast (2021-2025) (K Units)
Figure 89. Sales Channel: Direct Channel vs Indirect Channel
関節リウマチ治療の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Rheumatoid Arthritis Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 3.0% in the forecast period of 2020 to 2025 and will expected to reach USD 8402.6 million by 2025, from USD 7470.1 million in 2019. The Rheum…- クローン病治療薬の世界市場2020年：メーカー別、地域別、種類・用途別 Market Overview The global Crohn’s Disease Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Crohn’s Disease Drug mar…
- 関節リウマチ診断検査の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Rheumatoid Arthritis Diagnosis Tests market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 5.0% in the forecast period of 2020 to 2025 and will expected to reach USD 529.2 million by 2025, from USD 435.8 million in 2019. The R…
- クローン病診断・治療の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Crohn's Disease Diagnostic and Therapeutic market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Cr…
- 自己免疫治療薬の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Autoimmune Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Autoimmune Drugs market repo…